Eli Lilly's Breast Cancer Drug Inluriyo Approved by UK Regulator
MT Newswires Live
9 hours ago
Eli Lilly's (LLY) breast cancer drug Inluriyo has been approved by the UK's Medicines and Healthcare products Regulatory Agency, the regulator said Tuesday.
The treatment is for adults with a certain type of breast cancer that is locally advanced or has spread to other parts of the body and has not responded to hormone treatment, the regulator said, adding the drug can only be used in people who have some changes in a gene called ESR1.
Inluriyo is taken as a daily pill, the regulator said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.